The EXCEL Registry of Patients Requiring ECMO
Launched by AUSTRALIAN AND NEW ZEALAND INTENSIVE CARE RESEARCH CENTRE · Jan 2, 2019
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
The EXCEL Registry is a study looking at patients in Australia and New Zealand who need a special life-support treatment called ECMO (Extracorporeal Membrane Oxygenation). This treatment is used for people who are very sick, often with serious lung or heart problems. The goal of the study is to collect detailed information about these patients, including how they are chosen for ECMO, any complications that might arise, the costs involved, and their experiences after treatment. By gathering this data, researchers hope to identify areas where current practices can be improved.
To be eligible for this study, participants need to be adults who are admitted to a hospital and receive ECMO treatment in Australia or New Zealand. There are no specific exclusions, meaning anyone who meets the age requirement and receives ECMO can potentially take part. Those who join the study can expect to contribute to important research that may improve the care of future patients needing ECMO. The information collected will help healthcare providers understand the best practices and challenges related to this complex treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients admitted to adult hospitals and receive ECMO in Australia and New Zealand
- • Nil Exclusion Criteria
About Australian And New Zealand Intensive Care Research Centre
The Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) is a leading research organization dedicated to improving outcomes in critically ill patients through innovative clinical trials and research initiatives. Based at Monash University, the Centre fosters collaborative partnerships among clinicians, researchers, and institutions across Australia and New Zealand. Its focus on evidence-based practice and translational research aims to enhance the quality of intensive care, drive advancements in treatment protocols, and ultimately improve patient care in the intensive care unit (ICU) setting. ANZIC-RC is committed to addressing key challenges in critical care medicine, ensuring that findings from its trials contribute to better health outcomes and inform clinical guidelines globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Westmead, New South Wales, Australia
Liverpool, New South Wales, Australia
Brisbane, Queensland, Australia
Parkville, Victoria, Australia
Brisbane, Queensland, Australia
Hobart, Tasmania, Australia
Box Hill, Victoria, Australia
Frankston, Victoria, Australia
Launceston, Tasmania, Australia
Nedlands, Western Australia, Australia
Melbourne, Victoria, Australia
Chermside, Queensland, Australia
St Leonards, New South Wales, Australia
Clayton, Victoria, Australia
Heidelberg, Victoria, Australia
Sydney, New South Wales, Australia
Canberra, Australian Capital Territory, Australia
Sydney, New South Wales, Australia
Adelaide, South Australia, Australia
Auckland, , New Zealand
Camperdown, , Australia
Townsville, Queensland, Australia
Darlinghurst, New South Wales, Australia
Newcastle, New South Wales, Australia
Adelaide, South Australia, Australia
Melbourne, Victoria, Australia
Perth, Western Australia, Australia
Sunshine Coast, Queensland, Australia
Geelong, Victoria, Australia
Southport, Queensland, Australia
Richmond, Victoria, Australia
Patients applied
Trial Officials
Carol L Hodgson, PhD
Study Chair
Australian and New Zealand Intensive Care Research Centre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials